Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,051.03 0.17 (0.02%) as of 4:30 Fri 6/28


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 110.03(B)
Last Volume: 750,617 Avg Vol: 759,306
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,108 255,165 311,759 469,743
Total Sell Value $188,697,290 $247,812,013 $294,950,701 $405,465,351
Total People Sold 7 14 16 18
Total Sell Transactions 18 43 67 128
End Date 2024-03-31 2023-12-29 2023-06-30 2022-06-30

   
Records found: 1367
  Page 36 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Brown Michael S Director   –       •      –    2019-11-12 4 AS $349.00 $1,570,500 D/D (4,500) 323     -
   Brown Michael S Director   –       •      –    2019-11-12 4 OE $273.67 $1,231,515 D/D 4,500 4,823     -
   Stahl Neil EVP Research and Development   •       –      –    2019-11-08 4 S $330.56 $2,492,888 D/D (7,364) 22,455     -
   Goldstein Joseph L Director   –       •      –    2019-11-08 4 S $340.44 $340,440 D/D (1,000) 10,323     -
   Vagelos P Roy Chairman of the Board   •       •      –    2019-10-02 4 GD $0.00 $0 I/I 764 144,897     -
   Sanofi-Aventis   •       •       •   2019-09-10 4 S $281.15 $48,611,804 D/D (172,904) 20,550,813     -
   Yancopoulos George President and CSO   •       •      –    2019-08-05 4 GA $0.00 $0 I/I 75,036 328,352     -
   Yancopoulos George President and CSO   •       •      –    2019-08-05 4 GD $0.00 $0 I/I 75,036 0     -
   Vagelos P Roy Chairman of the Board   •       •      –    2019-07-02 4 GD $0.00 $0 I/I 669 145,661     -
   Yancopoulos George President and CSO   •       •      –    2019-06-13 4 GD $0.00 $0 I/I 500,000 253,316     -
   Yancopoulos George President and CSO   •       •      –    2019-06-13 4 GA $0.00 $0 I/I 500,000 500,000     -
   Stahl Neil EVP Research and Development   •       –      –    2019-05-24 4 GD $0.00 $0 D/D 1,300 21,150     -
   Vagelos P Roy Chairman of the Board   •       •      –    2019-05-24 4 D $313.64 $25,142,637 D/D (80,164) 388,505     -
   Vagelos P Roy Chairman of the Board   •       •      –    2019-05-24 4 OE $21.25 $3,268,080 D/D 153,792 468,669     -
   Goldstein Joseph L Director   –       •      –    2019-05-15 4 S $305.93 $305,930 D/D (1,000) 11,323     -
   Fenimore Christopher R. VP Controller   •       –      –    2019-04-18 4 GA $0.00 $0 I/I 350 1,897     -
   Fenimore Christopher R. VP Controller   •       –      –    2019-04-18 4 GD $0.00 $0 D/D 350 7,096     -
   Fenimore Christopher R. VP Controller   •       –      –    2019-04-18 4 OE $21.25 $7,438 D/D 350 7,446     -
   Vagelos P Roy Chairman of the Board   •       •      –    2019-04-15 4 GD $0.00 $0 I/I 514 146,330     -
   Schleifer Leonard S President & CEO   •       •      –    2019-03-21 4 OE $21.25 $2,125 D/D 100 424,062     -
   Sanofi-Aventis   •       •       •   2019-03-08 4 S $412.17 $54,041,316 D/D (131,115) 20,723,717     -
   Yancopoulos George President and CSO   •       •      –    2019-02-19 4 GA $0.00 $0 I/I 150,722 753,316     -
   Yancopoulos George President and CSO   •       •      –    2019-02-19 4 GD $0.00 $0 I/I 150,722 249,278     -
   Fenimore Christopher R. VP Controller   •       –      –    2019-01-18 4 GA $0.00 $0 I/I 150 1,547     -
   Fenimore Christopher R. VP Controller   •       –      –    2019-01-18 4 GD $0.00 $0 D/D 150 7,096     -
  1367 Records found
  Previous  30  31  32  33  34  35  36  37  38  39  Next   
  Page 36 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us